Cardiff Oncology (CRDF) has completed enrollment for the phase 2 trial assessing a combination of its onvansertib drug candidate with the standard of care in patients with first-line, RAS-mutated metastatic colorectal cancer.
Patients across 41 clinical sites in the US are randomized into either 20- or 30-milligram onvansertib plus standard of care, or standard of care alone. The study has a primary endpoint of an objective response rate and secondary endpoints including progression-free survival, duration of response and safety, the company said.
Cardiff said it expects to report additional clinical data from the mid-stage trial later during the current quarter.
Cardiff shares recently were fractionally higher during Tuesday's after-hours session.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。